Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug trial aims to tame overactive immune system in lupus patients

NCT ID NCT07371468

First seen Jan 31, 2026 · Last updated May 01, 2026 · Updated 13 times

Summary

This early-stage study tests an experimental drug called GSK5926371 in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that mistakenly attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults expected to join.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Fukuoka, 812-8582, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    Hiroshima, 734-8551, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    Hokkaido, 060-8648, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.